Trial reportFrontiers in immunology
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients.
Trial report in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04386395 (Whole Blood Immune Cells Characterization in Critically Ill COVID-19 Patients), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Whole Blood Immune Cells Characterization in Critically Ill COVID-19 Patients: A Prospective Study
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Pooled it
- Immunothrombosis in Acute Respiratory Dysfunction of COVID-19.Frontiers in immunologyPooled it
- A Longitudinal Study of Immune Cells in Severe COVID-19 Patients.Frontiers in immunologyTrial
- Induction of dysfunctional CD14Frontiers in immunology · 2026Article
- Age-Related Patterns of Type II Interferon Immunity: Implications for Intramacrophagic Infections and MSMD Diagnosis During Childhood.Journal of clinical immunology · 2025Article
- Identifying Key Hematological and Biochemical Indicators of Disease Severity in COVID-19 and Non-COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Exploratory analyses of leukocyte responses in hospitalized patients treated with ozanimod following a severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection.Immunology and cell biology · 2025Article
- Longitudinal Immune Profiling in Autoimmune Polyendocrine Syndrome Type 1.Scandinavian journal of immunology · 2025Article
- Different patterns of leukocyte immune responses to infection of ancestral SARS-CoV-2 and its variants.Frontiers in cellular and infection microbiology · 2025Article
- Immune-modulating therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) in refractory rhino-orbital-cerebral mucormycosis - a case report.Frontiers in immunology · 2025Article
- Article
- SARS-CoV-2 infection elucidates features of pregnancy-specific immunity.Cell reports · 2024Article
- Review
- Predictive value of systemic inflammatory index (SII) for the time to negative nucleic acid conversion in patients with mild COVID-19 by the omicron wave.Frontiers in medicine · 2024Article
- The significance of CD16+ monocytes in the occurrence and development of chronic thromboembolic pulmonary hypertension: insights from single-cell RNA sequencing.Frontiers in immunology · 2024Article
- Stratification of COVID-19 Severity Using SeptiCyte RAPID, a Novel Host Immune Response Test.Viruses · 2023Article
- Endotoxin tolerance and low activation of TLR-4/NF-κB axis in monocytes of COVID-19 patients.Journal of molecular medicine (Berlin, Germany) · 2023Article
- High-dimensional comparison of monocytes and T cells in post-COVID and idiopathic pulmonary fibrosis.Frontiers in immunology · 2023Article
- Case Report: Intercurrent infections in COVID-19-induced sustained immunodepression: is interferon gamma a suitable drug?Frontiers in immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2-specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR expression was below the 8,000 AB/C threshold defining acquired immunodepression. A "V" trend curve for lymphopenia, monocyte numbers, and HLA-DR expression was observed with a nadir between days 11 and 14 after symptoms' onset. Intermediate CD14 CLINICAL
trial registrationhttps://clinicaltrials.gov/, identifier NCT04386395.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.